PENNSAID (diclofenac sodium) by Amgen is (ak) is unknown. Approved for osteoarthritis of the knee. First approved in 2009.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
PENNSAID is a topical solution containing diclofenac sodium, approved by the FDA in November 2009 for the treatment of osteoarthritis pain in the knee(s). It is a nonsteroidal anti-inflammatory drug (NSAID) administered via topical route to provide localized pain relief. The product is currently in peak commercial lifecycle stage, sponsored by Amgen, and represents a differentiated delivery approach within the diclofenac market.
(AK) is unknown.
A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp
To Evaluate the Superiority of Fixed Combination (Orfenadrine 35mg, Acetaminophen 325mg, Caffeine 65mg and Diclofenac Sodium 50mg) Compared to Voltaren® (Diclofenac Sodium 50mg) in the Treatment of Acute Postural Low Back Pain.
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp
Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp
Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects With Acute Blunt Trauma Injuries
Worked on PENNSAID at Amgen? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~5 years — strategic planning for patent cliff underway
$135M Medicare spend — this is a commercially significant brand
PENNSAID supports 8 currently open roles spanning brand management, field sales, medical science liaisons (MSLs), and specialty marketing positions focused on rheumatology and primary care. Success in this role requires deep knowledge of NSAID pharmacology, osteoarthritis treatment algorithms, formulary navigation, and competitive positioning against multiple branded topical alternatives. The competitive landscape demands strong account management and payer negotiation skills to maintain market share against approaching generics and competing branded products.